Investors / Australia / Brandon Capital
Brandon Capital
Venture capital · Melbourne, Australia · Asia Pacific
Brandon Capital is a life science venture capital firm that invests in medical research and biotech companies, supporting them from proof-of-concept through to commercialisation. In Australia and New Zealand it sources deals through Brandon BioCatalyst, a collaboration of superannuation funds, CSL, governments and medical research institutes.
Invests inHealthcare & Biotech
In its own wordslife sciencesbiotechtherapeuticsmedical researchhealthcare
Your fit with Brandon Capital
Four questions about your startup
See how your round matches what it backs, point by point.
Or find every investor that fitsBrandon Capital lists 23 checked portfolio companies on its own site and is named in 6 funding rounds, 1 of them as lead. Its most frequent entry is Series B, 33% of the companies with a known first round. Its largest theme is Healthcare & Biotech (100%). 65% of its companies are based in Australia. It invests most often alongside Brandon BioCatalyst, Uniseed and Novartis Venture Fund.
Counts come from funding rounds that name Brandon Capital, complete from mid-2025: earlier rounds appear only when they were reported later. Round amounts and full round histories are on Fundup AI.
Round figures show recent activity, not Brandon Capital's whole history. Rounds on record name 6 companies; its own site lists 23. Funding rounds are complete from mid-2025, so counts and the yearly trend undercount a firm that invested before then. The portfolio, themes and places come from its own site and are not affected.
Entry stage
share of companies by the stage of its first roundShow as a table
| Value | |
|---|---|
| Pre-seed | 0% |
| Seed | 17% |
| Series A | 17% |
| Series B | 33% |
| Growth | 33% |
Activity by year
rounds it joined, last 10 yearsShow as a table
| Total | Rounds it led | |
|---|---|---|
| '17 | 0 | 0 |
| '18 | 0 | 0 |
| '19 | 0 | 0 |
| '20 | 0 | 0 |
| '21 | 0 | 0 |
| '22 | 0 | 0 |
| '23 | 0 | 0 |
| '24 | 0 | 0 |
| '25 | 4 | 0 |
| '26 | 2 | 1 |
Investor profile
percentile among all firmsShow as a table
| Measure | Percentile of all firms | Value |
|---|---|---|
| Portfolio size | 57th | 23 companies |
| Recent activity | 69th | 2 rounds in 12 months |
| Early stage | 57th | 17% of entries at pre-seed or seed |
| Evidence | 93th | 22% of companies confirmed by a round |
| Sector focus | 100th | 100% in its largest sector |
| Reach | 78th | 5 countries |
Invests most often with
firms sharing its portfolio companiesShow as a table
| Share | |
|---|---|
| Brandon BioCatalyst | 17 |
| Uniseed | 5 |
| Novartis Venture Fund | 4 |
| Stoic VC | 4 |
| Canaan | 2 |
| Omega Funds | 2 |
| Abingworth | 1 |
| Alphawave Group | 1 |
Its portfolio companies
where they are based, and what their own sites showSite status
- Site answers2296%
- No longer answers00%
- Points to another company14%
- Parked or sold domain00%
A site that stops answering three checks in a row is counted as no longer answering; that is not proof of closure. A site that points to another company is often an acquisition.
Investment themes
share of its checked companiesThis firmAll checked companies
Show as a table
| This firm | All checked companies | |
|---|---|---|
| Healthcare & Biotech | 100% | 15% |
Co-investor network
who it backs companies with, and who they back togetherAll co-investors or Compare portfolios with Brandon BioCatalyst
Compare Brandon Capital head to head
portfolio size, rounds, entry stages, themes and the companies both backThree or more firms at once: portfolio overlap.
Recent portfolio activity
when companies last raised with Brandon Capital| Date | Company | Stage |
|---|---|---|
| 15 Jul 2026 | Series C+ | |
| 13 Feb 2026 | Series C+ Led | |
| 22 Oct 2025 | Series B | |
| 8 Sept 2025 | Series B | |
| 13 Aug 2025 | Seed |
Round details for Brandon Capital
Amounts, full round histories and every co-investor in Brandon Capital's rounds are on Fundup AI. VCinfo covers investors and their portfolios.
Portfolio
23 companies checked against their own sites| Company | What it does | Themes | First round with it | Evidence |
|---|---|---|---|---|
| AdvanCell is a clinical-stage radiopharmaceutical company developing targeted alpha therapies for cancer treatment. | Healthcare & Biotech | Jul 2026Series C+ | Page + round | |
| Aravax is dedicated to developing next-generation immunotherapies for the treatment of food allergy | Healthcare & Biotech | Portfolio page | ||
| AstronauTx develops therapeutics to treat neurological disorders by improving sleep architecture | Healthcare & Biotech | Portfolio page | ||
| Axelia Oncology develops therapies for cancer patients using the body's immune system. | Healthcare & Biotech | Portfolio page | ||
| Azura Ophthalmics develops treatments for ophthalmic conditions using keratolytics | Healthcare & Biotech | Portfolio page | ||
| CatalYm is developing a safe and efficacious immune therapy for solid tumors. | Healthcare & Biotech | Portfolio page | ||
| Certa Therapeutics develops precision therapies for patients with inflammatory and fibrotic diseases | Healthcare & Biotech | Portfolio page | ||
| Cincera Therapeutics is a privately held biotechnology company focused on the discovery and development of new drugs aiming to treat inflammatory and fibrotic conditions associated with metabolic diseases. | Healthcare & Biotech | Portfolio page | ||
| Currus Biologics is developing its proprietary BEAT technology for solid tumours | Healthcare & Biotech | Portfolio page | ||
| Denteric is developing a novel therapy called GPV381 for chronic inflammation. | Healthcare & Biotech | Portfolio page | ||
| EBR Systems develops and manufactures a leadless left ventricular endocardial pacing device for heart failure treatment. | Healthcare & Biotech | Portfolio page | ||
| ENA Respiratory is a clinical-stage pharmaceutical company developing antiviral host defense enhancers for the prevention of severe complications from respiratory viral infections in vulnerable populations. | Healthcare & Biotech | Oct 2025Series B | Page + round | |
| George Medicines develops single-pill combination therapies for non-communicable diseases | Healthcare & Biotech | Portfolio page | ||
| Mirugen is a company that programs cells to restore health, with a focus on restoring sight | Healthcare & Biotech | Aug 2025Seed | Page + round | |
| MycRx is developing oral, small molecule inhibitors that directly target Myc, oncology's 'mega target' | Healthcare & Biotech | Portfolio page | ||
| Myricx Bio is a biotech company discovering and developing a novel class of payloads for antibody drug conjugates to treat cancer. | Healthcare & Biotech | Portfolio page | ||
| NRG Therapeutics is developing innovative oral medicines for amyotrophic lateral sclerosis and Parkinson's | Healthcare & Biotech | Sept 2025Series B | Page + round | |
| OncoRes Medical is developing an intraoperative imaging technology to provide surgeons with real-time assessment of tissue microstructure. | Healthcare & Biotech | Feb 2026Series C+ | Page + round | |
| Pathios Therapeutics is a clinical-stage oncology and immunology company that targets the acid-sensing GPCR, GPR65, to transform cancer outcomes | Healthcare & Biotech | Portfolio page | ||
| Pheon Therapeutics is developing next generation Antibody-Drug Conjugates for a wide range of hard-to-treat cancers | Healthcare & Biotech | Portfolio page |
About this data
site last read 5 Nov 2026- Site
- brandoncapital.vc
- Last read
- 5 Nov 2026
- Watching since
- 6 Nov 2026
- Rounds since
- 13 Aug 2025
- Companies checked
- 23
Rates come from what VCinfo has observed since observation_start. Firms tend to remove companies that closed, so early rates understate reality. A company leaving a portfolio page does not mean it closed or exited. An unreachable site means our checks failed, nothing more.
Get Brandon Capital's profile as data
Pull Brandon Capital's portfolio, co-investors and changes through one API key or MCP, open every portfolio row, compare it with other firms, and get an email when it adds a company or files a fund.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/firms/brandoncapital.vc
# also
GET /v1/firms/brandoncapital.vc/portfolio
GET /v1/firms/brandoncapital.vc/coinvestors
GET /v1/firms/brandoncapital.vc/news